Last reviewed · How we verify

Rakuten Medical, Inc. — Portfolio Competitive Intelligence Brief

Rakuten Medical, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Physician's Choice SOC Physician's Choice SOC phase 3 X-ray activated photodynamic therapy agent Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Rakuten Medical, Inc.:

Cite this brief

Drug Landscape (2026). Rakuten Medical, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rakuten-medical-inc. Accessed 2026-05-16.

Related